No. | Product Name | Grade | DMF /ASMF | CEP Planned | CAS No | Therapeutic Category |
---|---|---|---|---|---|---|
1 | Acamprosate Calcium | EP | ✔ | ✔ | 77337-73-6 | Reduces alcoholism cravings. |
2 | Acyclovir | USP/EP | ✔ | 59277-89-3 | Antiherpesvirus agent | |
3 | Apixaban | ICH | ✔ | 503612-47-3 | Anticoagulant | |
4 | Bempedoic Acid | ICH | ✔ | 738606-46-7 | Treatment of hypercholesterolemia | |
5 | Carbocisteine | EP | ✔ | ✔ | 638-23-3 25390-17-4 (DL) | Chronic obstructive pulmonary disorder |
6 | Dapagliflozin Base | ICH | ✔ | 461432-26-8 | Treat type 2 diabetes (Antidiabetic medication) | |
7 | Dapagliflozin Propanediol Monohydrate | ICH | ✔ | 960404-48-2 | Treat type 2 diabetes (Antidiabetic medication) | |
8 | Dexlansoprazole Sesquihydrate | ICH | ✔ | 313640-86-7 | New-generation proton pump inhibitor | |
9 | Edoxaban Tosylate Monohydrate | ICH | ✔ | 1229194-11-9 | Anticoagulant | |
10 | Eltrombopag Olamine | ICH | ✔ | 496775-62-3 | Treat thrombocytopenia (abnormally low platelet counts) | |
11 | Empagliflozin | ICH | ✔ | 864070-44-0 | Antidiabetic medication | |
12 | Febuxostat | ICH | ✔ | 144060-53-7 | High uric acid levels. | |
13 | Iron Hydroxide Polymaltose Complex | IH | ✔ | 53858-86-9 | To treat iron deficiency / iron deficiency anemia | |
14 | Lisdexamfetamine Dimesylate | ICH | ✔ | 608137-32-2 | Attention deficit hyperactivity disorder | |
15 | Mesalamine | EP | ✔ | 89-57-6 | To treat inflammatory bowel disease, including ulcerative colitis and Crohn's disease | |
16 | Mirabegron | EP | ✔ | ✔ | 223673-61-8 | To treat overactive bladder |
17 | Quetiapine Fumarate | EP/USP | ✔ | ✔ | 111974-72-2 | Major depressive disorder |
18 | Rivaroxaban | EP/USP | ✔ | ✔ | 366789-02-8 | Anticoagulant |
Note: The listed products would be offered only in countries where the products do not constute a patent infringements. However the customer would exclusively hold the final responsibility. Enlisted products/Patent Protected products available are solely offered for experiment use or under Bolar provision Strictly in compliance with the respecve country law.